5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Alivus Life Sciences Ltd.

•
alivus.comBSE: 543322NSE: ALIVUS
Market Cap₹ 17,006 Cr.
Current Price
High / Low₹ 1,494 / 819
Stock P/E28.2
Book Value₹ 284
Price to Book3.60
Dividend Yield0.36 %
ROCE24.6 %
ROE18.4 %
Face Value₹ 2

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 26.1%
  • Latest quarter profit grew 31.7% YoY, showing strong momentum
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 0.90x)
  • Company has a consistent dividend-paying track record

CONS

  • Promoter holding has decreased over last 2 years: -8.0pp
  • Company has delivered a poor sales growth of 6.2% over past five years
  • Company has delivered a poor profit growth of 9.9% over past five years
  • Though reporting repeated profits, the company pays out little dividend (10.9%)
  • Expensive relative to growth - PEG of 4.3

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.ALIVUS1385.1528.2017005.690.36160.0831.71640.416.4124.6133.06
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
578595573537589507642650602588673689640
385428400395429373452451430409442475451
Operating Profit193167173141159134190198172179231215190
OPM %33.39%28.06%30.12%26.36%27.10%26.51%29.65%30.55%28.63%30.47%34.37%31.13%29.64%
2523591010915-122322
Interest0000000111111
Depreciation13131315141515161718202021
Profit before Tax182159161130150127185191163174198216212
Tax %25.58%25.29%26.09%24.48%25.80%25.22%26.03%25.84%25.43%25.33%24.26%24.62%24.57%
Net Profit1351191199811195137142122130150163160
11.059.699.697.999.107.7811.1811.579.9110.6012.2513.2313.04

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
08861,5371,8852,1232,1612,2832,3872,5522,590
06391,0651,2941,5071,5191,6091,7041,7551,776
Operating Profit-0247472591616642674683797815
OPM %-5.24%27.88%30.70%31.35%29.02%29.72%29.53%28.60%31.24%31.45%
01121152912353548
Interest0134882812255
Depreciation0192933384253617579
Profit before Tax-0228421471565629631654751801
Tax %-3238.46%14.33%25.64%25.35%25.88%25.72%25.41%25.76%24.87%24.67%
Net Profit-0196313352419467471486564603
EPS-433.821355.761597.3732.6135.6338.1138.4339.6345.99—
Dividend Payout %0.00%0.00%0.00%0.00%61.45%55.10%58.55%12.62%10.87%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
6%
3 Years:
6%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
10%
3 Years:
7%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
—
1 Year:
47%

RETURN ON EQUITY

10 Years:
—
5 Years:
22%
3 Years:
19%
Last Year:
18%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Sep 1

₹ 2.50

Rs.5.0000 per share(250%)Final Dividend

2025

Sep 1

₹ 2.50

Rs.5.0000 per share(250%)Final Dividend

2023

Oct 17

₹ 11.25

Interim Dividend

2023

Mar 24

₹ 10.50

Interim Dividend

2022

Sep 15

₹ 5.25

Rs.10.5000 per share(525%)Final Dividend

2021

Nov 22

₹ 5.25

Rs.10.5000 per share(525%)Interim Dividend

2026

Aug 6

₹ 2.50

Rs.5.0000 per share(250%)Final Dividend

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital02222525252525
-1864007512,0262,1072,2972,7833,300
0000117155149
Trade Payables0183201221308427369390372
11,2041,1231,247474645823505411
Total Liabilities01,4751,7262,2212,8343,2203,5283,7544,157
04565465735907818059551,038
Capital Work in Progress0801114924910194273
0000000478780
0401413513516604667674692
0000007659701,073
Cash & Bank0210116512309302712
05367461,0051,1241,477888512299
Total Assets01,4751,7262,2212,8343,2203,5283,7544,157

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
-034288497736460414392565
Cash from Investing0-9-51-69-122-147-116-616-570
Cash from Financing01-137-214-79-388-279-6-64
028106397-22818-230-69

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
82.8575.0075.0074.9974.9474.9174.9174.8774.87
4.817.856.746.576.426.845.085.305.54
1.574.164.865.195.625.477.137.277.18
Government0.000.000.000.000.000.000.000.000.00
Public10.7612.9913.4013.2513.0312.7812.8812.5612.41

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-11
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-11 - Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

2026-09-08
Shareholders meeting

2026-09-08 - Alivus Life Sciences Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 08, 2026. Further, the company has submitted the Exchange a copy of Scrutinizers report along with voting results.

2026-09-07
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-07 - Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

2026-09-05
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-05 - Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

2026-08-25
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-25 - Alivus Life Sciences Limited has informed the Exchange about Schedule of Investor/Analyst meeting

2026-08-18
Press Release

2026-08-18 - Alivus Life Sciences Limited has informed the Exchange regarding a press release dated August 18, 2026, titled "Alivus Life Sciences announces acquisition of majority stake in IQGenX.".

2026-08-18
Outcome of Board Meeting

2026-08-18 - Enclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.

2026-08-13
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-13 - Alivus Life Sciences Limited has informed the Exchange about Schedule of meet of Investor/Analyst.

2026-08-13
Copy of Newspaper Publication

2026-08-13 - Alivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 15th Annual General Meeting and e-voting information.

News

Recent coverage and analyst commentary for ALIVUS

Loading news…

🤖

AI Stock Analyst

Alivus Life Sciences Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login